Member Info for Laura2022

Manfor

Afternoon, good talking points there

Have you purchased any as yet

Manfor

1 because market is inefficient

2 because only preliminary discussions

3 no one formally made bid to start ball rolling

Kendal

I filtered him 12mths ago

Talks utter nonsense on most boards

Yes..2 weeks ago major outlets quoted the same price of c £1.5bln

Its absolutely capitualtion point at 66p and fact it switched so quickly to now being able to sell £15-20k at a time , above advertised bid price

With main holder at 29%

The 'preliminary " is and was why its still £2.05-2.10

Eg below from the articles 2 weeks ago

Private healthcare group Spire has revealed it is in talks regarding a possible takeover by a group of private equity firms that could see it valued at £1.5 billion.

The FTSE 250 company said it was in discussions with buyers, including private equity groups Bridgepoint and Triton, but stressed they were at a 'preliminary stage' with no certainty of an offer.

GB2

They CANT release shares on a DIFFERENT price to the original terms

See the rns

Thanks LTB

Might have to add more , hopefully the takeoverof SPI comes before their 21st Feb and I can add big here

Simply because ( not silly !)

Kendal

Also, there have been many bids last 12mths where its been at large premium EVEN IF there had been behind scenes offers

Eg most recently BEZ

Sky news wouldn't have quoted £3.50 lart month based just on conjecture

The fact its £2.05 is silly because no suitor has broken rank yet

Block buyer continued

66p is a price that values Transense at just £10mill .

Around £8mill still to come from Bridgestone and over £1mill spent on pilot production line and around £1 mill in the bank and shares held in the treasuary.

Retired; Banker

Like us :)

Now 66.4p to buy :),

Best wishes

Strange 2nd post after 12mths on AMOI etc

Mmmmm

Feel free to cash out then if you actually hold

Strange 2nd post after 12mths on AMOI etc

Mmmmm

While the demand was materially greater than this level, the Company was limited by its authorities, with the Additional Subscription Shares being issued using the additional authorit

Excellent news !!

GENinCode (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, is pleased to announce that further to the Fundraising initially announced on 21 January 2026, it has received addition demand